PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity | Zendy

Alessandro Poli | Zendy; Shidqiyyah Abdul-Hamid | Zendy; Antonio Enrico Zaurito | Zendy; Francesca Campagnoli | Zendy; Valeria Bevilacqua | Zendy; Bhavwanti Sheth | Zendy; Roberta Fiume | Zendy; Massimiliano Pagani | Zendy; Sergio Abrignani | Zendy; Nullin Divecha | Zendy

Open Access

PIP4Ks impact on PI3K, FOXP3, and UHRF1 signaling and modulate human regulatory T cell proliferation and immunosuppressive activity

Author(s) -

Alessandro Poli,

Shidqiyyah Abdul-Hamid,

Antonio Enrico Zaurito,

Francesca Campagnoli,

Valeria Bevilacqua,

Bhavwanti Sheth,

Roberta Fiume,

Massimiliano Pagani,

Sergio Abrignani,

Nullin Divecha

Publication year - 2021

Publication title -

proceedings of the national academy of sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.011

H-Index - 771

eISSN - 1091-6490

pISSN - 0027-8424

DOI - 10.1073/pnas.2010053118

Subject(s) - immune system , foxp3 , druggability , biology , immunity , immunology , regulatory t cell , microbiology and biotechnology , cell growth , function (biology) , t cell , cancer research , il 2 receptor , gene , genetics

Significance PIP4Ks are druggable lipid kinases critical in cancer biology whose function in human immunity remains unknown. Here, we show that PIP4Ks specifically control the growth and activity of a subset of human immune cells called Tregs, isolated from the blood of healthy donors. Tregs function to exquisitely control the strength of the immune response. If the immune response is too strong, this can trigger autoimmune disease insurgence, while weak responses can lead to increased infections or enable tumor cell growth. Being able to selectively control Treg activity would impact the strength of immune responses and ultimately how we treat human diseases. Accordingly, we show that a drug-like inhibitor of PIP4K can be used to control Treg cell activity.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research